Point-of-Care Glucose Testing Market to Witness Growth 3.85% by 2030

The global Point-of-Care Glucose Testing market size is expected to be worth around US$ 6,217.90 million by 2030 from valued at US$ 10.05 million in 2020 and is anticipated to grow at a CAGR of 3.85% from 2021 to 2030.

Report Highlights

• The others product segment accounted for the largest share of more than 54.05% of the global revenue in 2021 and will continue expanding at a steady CAGR during the forecast period.
• North America dominated the global market in 2021. The regional market accounted for the largest share of over 40.11%.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/36814

• Point-of-care testing for glucose monitoring is a valuable tool for managing patients with diabetes in the outpatient settings. Coupling of POCT glucose monitoring devices and electronic medical records enable test results to be shared instantly with care providers. Potential operational benefits with more rapid decision making, reduced operating times, and high-dependency boost the market growth of point-of-care glucose testing.
• Increase in prevalence of diabetic patients, rise in preference for home health care across the globe, and technological advancement done by various key players drive the growth in global level. For instance, GlucoTrack, which is manufactured by Integrity Applications (Israel), performs quantification using electromagnetic, ultrasonic, and thermal waves in combination. As per the WHO, number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. According to a paper published by Massachusetts General Hospital, about 600,000 POC tests per year are performed by physicians and nurses in the institution.

Growth Factors

An increase in the demand for point-of-care testing (POCT) has been witnessed in recent years. As compared to the conventional laboratory testing performed central lab settings, glucose POCT aids in performing effective diagnosis at the patient’s bedside. Easy and convenient operation of POCT has largely favored the growing usage of glucose meters across medical settings. 

The demand for performing bedside monitoring of blood sugar levels efficiently in a capillary blood sample and the need to ensure better management of carbohydrate metabolism has propelled the point-of-care glucose testing market players to launch innovative glucose meters in the market. Various companies are investing in the development of needle-less blood glucose monitoring devices to offer painless management of diabetes in patients.

For instance, GlucoTrack - a product manufactured by Integrity Applications (Israel) performs quantification using electromagnetic, ultrasonic, and thermal waves in combination. In addition, Eversense is another painless glucose monitoring subcutaneous implant offered by Senseonics. This implant is able to quantify glucose levels in interstitial fluid when placed beneath the skin. This is followed by data transmission to show the results in real time.

The latest no-code monitoring systems help in minimizing the errors that occur due to incorrect entry of strip codes. Whereas, others are incorporating noble metals such as silver, gold, and platinum which effectively reduces the electrical noise further improving accuracy.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36814

Key Drivers and Restraints of Global Point-of-Care Glucose Testing Market

• Increase in cases of diabetic patients across the world is expected to fuel the market growth. As per an article published in NCBI in 2017, prevalence of diabetes in the U.S. is likely to increase by 54% which is more than 54.9 million, between 2015 and 2030. According to the International Diabetes Federation, global prevalence of diabetes patients in 2019 was approximately 9.3% (463 million people). It is anticipated to rise to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. IDF stats also depict that number of diabetes patients in Europe is likely to rise from approximately 33 million in 2010 to 38 million in 2030.
• Technological innovations that provide early, safe, and accurate results for diagnosis tend to make a serious impact in the market. The advanced technology helps in continually updating the market by bringing on better products. Companies are launching technologically advanced devices for hassle-free testing experience. In 2016, Roche launched Accu-Chek Guide blood glucose monitoring system that offers a new spill-resistant SmartPack vial and a unique strip design with a large easy-edge dosing area.
• Accuracy of tests is one of the restraining factors for the market growth. Often, cases of false negative and false positive tests have been reported. This amounts to misdiagnosis even though these tests have been developed after severe R&D.

Fingertip to Lead Global Point-of-Care Glucose Testing Market

• Based on testing site, the global point-of-care glucose testing market can be divided into fingertip and alternate site testing
• Fingertip is expected to dominate the global market in terms of revenue generation. Finger-stick blood samples for blood glucose testing is a traditional way of monitoring the glucose level in patients. However, alternate site testing is expected to grow with the highest CAGR during the forecast period, owing to its various advantages over the traditional one such as less pain and sparing of fingertips.
• Accu-Chek FastClix lancing device which is a product of Roche Diabetes Care, Inc. can be used for both alternate sites and fingertip testing

Homecare Settings Segment to Witness Highest Growth

• Based on end-user, the global point-of-care glucose testing market can be divided into professional diagnostic centers, hospitals & clinics, home care settings, and others
• The home care settings segment dominated the global point-of-care glucose testing market. The segment is expected to grow at the highest rate during the forecast period. Rise in demand for home care settings is due to increased acceptance of home health care, technological advancements, and cost-effective alternatives compared to other modalities.

Product Insights

The others product segment accounted for the largest share of more than 54.05% of the global revenue in 2021 and will continue expanding at a steady CAGR during the forecast period. POC monitoring devices allow home-based self-monitoring of blood glucose levels and help patients perform routine activities with ease. These devices are also being used in inpatient settings as they are easy to use while offering quick results. Several glucose meters have been launched in the industry to suffice the significant need for diabetes monitoring technologies across hospitals, clinics, and other medical settings.

The Accu-Chek Inform II segment held the second-largest share in 2021. The FreeStyle Lite product segment is expected to witness the fastest growth rate over the forecast period. FreeStyle Lite is offered by Abbott and is available in discreet size with an in-built portlight and backlight, which makes it user-friendly for patients with a busy lifestyle. The product is used for measuring blood sugar from samples collected from fingers, forearm, hand, upper arm, and thigh. It is recommended to use the FreeStyle Lite meter only with the FreeStyle control solution and testing strips as the usage of other control solutions and test strips can yield inaccurate results.

Regional Insights

North America dominated the global market in 2021. The regional market accounted for the largest share of over 40.11% of the overall revenue in the same year. It is expected to maintain its lead even during the forecast period. This region is home to several key market players, such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC. This has increased the availability of glucose testing products, thereby contributing to the revenue generation of the regional market. In addition, higher healthcare expenditure by governments on diabetes management is one of the factors responsible for the regional market growth.

The adoption of POC tests is rapidly increasing owing to their associated advantages, such as fast, easy, and mobile diagnosis and self-monitoring. These products facilitate diagnosis and monitoring for patients at hospitals, health assessment centers, clinics, and homes. Rapidly developing healthcare infrastructure and the high prevalence of diabetes are the key factors expected to drive the market in Asia Pacific. Furthermore, a rise in the adoption of miniaturized models and various measures being taken for reducing stays in hospitals and clinics are expected to boost the product demand. The adoption of POC glucose diagnostics in Operating Rooms (ORs), emergency rooms, Intensive Care Units (ICUs), path labs, and hospitals is expected to increase owing to the early and efficient delivery of results.

Key Players

F. Hoffmann-La Roche Ltd., Abbott, Nipro, Nova Biomedical, ACON Laboratories, Inc., Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, and EKF Diagnostics.

Market Segmentation

• Product Outlook 
  • Accu Check Aviva Meter
  • Onetouch Verio Flex
  • i-STAT
  • Bayer CONTOUR blood glucose monitoring system
  • Freestyle Lite
  • True Metrix
  • Accu-Chek Inform II
  • StatStrip
• Regional Outlook 
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36814

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333